NCT06401044View on ClinicalTrials.gov

A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease

PHASE1RecruitingINTERVENTIONAL
Enrollment

88

Participants

Timeline

Start Date

May 30, 2024

Primary Completion Date

February 22, 2027

Study Completion Date

August 13, 2027

Conditions
Thyroid Eye Disease
Interventions
DRUG

AMG 732

SC injection

OTHER

Placebo

SC injection

Trial Locations (5)

2065

NOT_YET_RECRUITING

North Shore Private Hospital, Saint Leonards

2113

NOT_YET_RECRUITING

Macquarie University Hospital, Sydney

32204

RECRUITING

Levenson Eye Associates, Jacksonville

34744

RECRUITING

Ilumina Medical Research, Kissimmee

89113

RECRUITING

Ppd Las Vegas Research Unit, Las Vegas

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY

NCT06401044 - A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease | Biotech Hunter | Biotech Hunter